New ValiMed™ Medication Validation System Demonstrates USP 797 Compliance at ASHP Summer Meeting
Baxa Corporation demonstrates the next-generation ValiMed System for medication safety at booth no. 729 at the American Society of Health-System Pharmacists Summer Meeting June 25 – 28 in Orlando, Fla. The next-generation ValiMed Technology offers the same benefits as the original system, with additional reporting features and a smaller sample requirement.
Englewood, CO (PRWEB) June 26, 2006
Baxa Corporation announces the release of the next-generation ValiMed Medication Validation System at the summer meeting of the American Society for Health-System Pharmacists. The ValiMed System validates medications and concentrations; allowing users to detect counterfeit products for brand protection, provide quality assurance for compounded products, and detect narcotic loss. The ValiMed System ensures patient safety in real time, by verifying that medications are correctly compounded.
ValiMed features patent-pending technology that validates in seconds the strength of compounded doses of high risk medications prior to dispensing. Verification of compounding accuracy and sterilization is a requirement under USP 27-NF 22 Chapter 797, which regulates the compounding of sterile products. The ValiMed System can play a key role in demonstrating the safety of compounded sterile products (CSPs) under these requirements.
The updated version of the ValiMed System – shown for the first time at the ASHP meeting – incorporates reports used to comply with USP 797 requirements. It also features a modified disposable, requiring a reduced sample volume for testing. “This next-generation ValiMed System addresses customer requests.” notes Product Manager Mark Thrasher. “It’s more robust and the smaller sample requirement more easily accommodates current pharmacy work flows.”
During the meeting, Baxa representatives will demonstrate the ValiMed System’s capabilities in their booth, number 729. Pharmacists will see first-hand how the system ensures the accuracy of their compounded solutions and helps them meet both USP 797 verification and JCAHO requirements for patient safety.
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Belgium, Denmark, Finland, France, Germany, Luxembourg and The Netherlands; and distribution partners worldwide. Further information is available at http://www. baxa. com (http://www. baxa. com).
About CDEX, Inc.
CDEX Inc. (OTCBB: CEXI), the manufacturer of the ValiMed System, is a technology development company focused on producing equipment that uses using chemical detection and validation technologies. CDEX technology is focused currently on two distinct areas: (i) identification of substances of concern (e. g., explosives and illegal drugs); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance. CDEX is headquartered in Rockville, Maryland, with a primary research and development laboratory in Tucson, Arizona. For more information, visit http://www. cdex-inc. com (http://www. cdex-inc. com) and http://www. valimed. com (http://www. valimed. com).
Contacts:
Marian Robinson, Vice President, Marketing
Baxa Corporation http://www. baxa. com (http://www. baxa. com) 800.567.2292 ext. 2157 or 303.617.2157
Maggie Chamberlin Holben, APR
Absolutely Public Relations http://www. absolutelypr. com (http://www. absolutelypr. com) 303.984.9801 or 303.669.3558
###
